Fady Ibraham Malik, Executive Vice President of Research and Development at Cytokinetics Inc (NASDAQ:CYTK), filed a Form 4 on November 18, 2026, disclosing option exercises and open-market share sales transacted on November 17, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Malik exercised 3,500 non-qualified stock options at an exercise price of $7.80 per share on November 17, 2026, acquiring 3,500 shares of common stock.
  • First sale tranche: 3,300 shares were sold at a weighted average price of $51.73 per share, with individual prices ranging from $51.39 to $52.37 per share.
  • Second sale tranche: 200 shares were sold at a weighted average price of $52.59 per share, with individual prices ranging from $52.52 to $52.66 per share.
  • Remaining beneficial ownership: Following all reported transactions, Malik directly holds 153,902 shares of common stock.
  • Remaining options: 9,386 non-qualified stock options (expiring February 27, 2028) remain beneficially owned following the exercise.
  • Rule 10b5-1 plan: The filing indicates the transactions were made pursuant to a contract, instruction, or written plan satisfying the affirmative defense conditions of Rule 10b5-1(c).

Cytokinetics EVP Research and Development Exercises Options and Sells Common Stock

According to the Form 4 filed with the SEC on November 18, 2026, Fady Ibraham Malik, EVP Research and Development at Cytokinetics Inc, reported three transactions in the company's common stock, all dated November 17, 2026. The filing identifies Malik as an officer of the issuer and notes the transactions were executed under a Rule 10b5-1(c) written plan.

The filing discloses that Malik first exercised 3,500 non-qualified stock options at an exercise price of $7.80 per share, bringing his directly held common stock position to 157,402 shares. He then sold 3,300 shares at a weighted average price of $51.73, with the actual per-share prices ranging from $51.39 to $52.37. A further 200 shares were sold at a weighted average price of $52.59, with per-share prices ranging from $52.52 to $52.66, according to the filing. The filing states that upon request, Malik undertakes to provide information regarding the number of shares sold at each separate price within those ranges.

After all three transactions, the filing reports Malik's direct beneficial ownership at 153,902 shares of common stock. His remaining non-qualified stock option position, exercisable from March 27, 2018, through February 27, 2028, at $7.80 per share, stands at 9,386 options, according to the disclosure. The form was signed by Jeff Hessekiel as attorney-in-fact for Dr. Malik on November 18, 2026.

What Was Disclosed

The filing reports a November 17, 2026, option exercise of 3,500 shares at $7.80 and two subsequent sales totaling 3,500 shares at weighted average prices of $51.73 and $52.59, conducted under a Rule 10b5-1 plan, leaving Malik with 153,902 shares directly held.